Grifols Finds Parkinson’s Biomarkers 12 Years Before Diagnosis in 2,600-Sample Study
Grifols’ Chronos-PD study profiled over 2,600 longitudinal plasma samples and measured more than 25,000 proteins to reveal early molecular signals emerging up to 12 years before Parkinson’s disease diagnosis. The analysis identified both known and novel biomarkers, including modulation of the CXCL12–cell adhesion–integrin axis, supporting precision medicine.
1. Study Design and Sample Profiling
Grifols leveraged its Alkahest subsidiary to analyze over 2,600 longitudinal plasma samples collected up to 12 years pre-diagnosis and nine years post-diagnosis, profiling more than 25,000 protein types across four proteomics platforms. This deepest proteomic study in PD to date integrates AI with real-world data for robust biomarker discovery.
2. Key Early Biomarker Discoveries
Researchers confirmed previously identified Parkinson’s biomarkers and uncovered novel early signals, notably a major modulation of the CXCL12–cell adhesion molecules–integrin signaling network, implicated in neuroinflammation and blood-brain barrier integrity. These reproducible molecular patterns across independent cohorts may enable stratified patient selection and early detection tools.
3. Chronos Platform and Future Applications
Chronos is part of Grifols’ broader program harnessing over 100 million proprietary plasma samples linked to real-world health data spanning thousands of conditions. The validated platform aims to expand biomarker discovery in other diseases and accelerate development of diagnostics and disease-modifying therapeutics at population scale.